Skip to content

Anti-ageing Efficacy of a Cosmetic Formulation Containing NMN (2%) Versus Placebo

Efficacy Evaluation of the Anti-ageing Effect of a Cosmetic Active Versus Placebo

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04685096
Enrollment
89
Registered
2020-12-28
Start date
2020-12-12
Completion date
2021-04-16
Last updated
2021-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatigue, Puffiness Around the Eyes, Wrinkle

Keywords

Skin aging

Brief summary

The study aims at evaluating skin wrinkling, puffiness and fatigue and dark circle appearance on asian and african-american healthy volunteer cohorts receiving a cosmetic formulation containing NMN (2%). The product will be evaluated after 28 and 56 days of twice-daily application in comparison with a reference cosmetic formulation using clinical scoring under dermatological control. Cosmetic acceptability and future use will also be subjectively evaluated by analysis of the subjects answers to an evaluation questionnaire.

Interventions

OTHERTest product creme

twice daily application of creme containing 2% NMN

OTHERReference creme

twice daily application of reference creme

Sponsors

Eurofins
CollaboratorINDUSTRY
LGD
CollaboratorINDUSTRY
Seneque SA
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
40 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy subject * Subject having given her free informed, written consent * Subject willing to adhere to the protocol and study procedures * Subject with normal frontal temperature lower than 37.5°c/100.4°F * Subject has read and understood the information given by the investigator related to protection against Novel Coronavirus 19 and necessity to contact the investigator in case of any suspicion of COVID related manifestation (increase of frontal temperature, cough, sore muscles, weakness…) during the study

Exclusion criteria

* Pregnant or nursing woman or woman planning to get pregnant during the study * Start, stop or change in hormonal treatment (including contraceptive pill) \<1.5 months * Cutaneous pathology on the study zone (face) * Use of topical or systemic treatment during the previous weeks liable to interfere with the assessment of the cutaneous efficacy of the study product * Subject having undergone a surgery under general anesthesia within the previous month * Know allergy to certain cosmetic or dermato-pharmaceutic products * Subject having done injections on face and/or a lifting * Excessive exposure to sunlight or UV-rays within the month preceding the study

Design outcomes

Primary

MeasureTime frameDescription
WrinklesChange from baseline (day 0) at days 28 and 56 of applicationclinical grading under dermatological control using 1) a 7 points Visual scale of Bazin from absence (0) to pronounced wrinkles (6) for the Asian panel and 2) a 5 points Visual scale of Bazin from absence (0) to pronounced wrinkles (4) for the Afro-American panel
Eye bagsChange from baseline (day 0) at days 28 and 56 of applicationclinical grading under dermatological control using 1) a 7 points Visual scale of Bazin from absence (0) to pronounced bags (6) for the Asian panel and 2) a 6 points Visual scale of Bazin from absence (0) to pronounced bags (5) for the Afro-American panel
Dark circlesChange from baseline (day 0) at days 28 and 56 of applicationclinical grading under dermatological control using 1) a 6 points Visual scale of Dermscan from absence (0) to important dark circles (6) for the Asian panel and 2) a 5 points Visual scale of Dermscan from absence (0) to important dark circles (4) for the Afro-American panel
Relaxed featuresChange from baseline (day 0) at days 28 and 56 of applicationclinical grading under dermatological control using a 11 points Non structured scale from relaxed features (0) to looking tired (10) for both panels

Secondary

MeasureTime frameDescription
Subjective evaluation of the product agreeableness and its effects on skin texture, moisture, puffiness, brightness, youth, swelling, wrinkling, radiance and tone.At day 28 of applicationSelf-assessment questionnaire on a 5 points scale from I disagree (-2) to I agree (+2).

Countries

China, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026